Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus

Amgen Reports Third Quarter 2021 Financial Results

November 2, 2021 4:01 PM EDT

THOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2021. Key results include:

Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 4% globally, driven by double-digit volume growth across a number of our products, including Prolia® (denosumab), EVENITY® (romosozumab-aqqg), Repatha® (evolocumab) and MVASI® (bevacizumab-awwb).GAAP earnings per share (EPS) decreased 3% to $3.31 driven by a $400 million licensing-related... More